New drug IPG1094 gets first human test in china
NCT ID NCT07679113
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This phase 1 trial tests the drug IPG1094 in 24 healthy Chinese adults to understand how the body absorbs, processes, and eliminates it. Part A examines whether food affects a single dose, while Part B looks at repeated dosing over 10 days. All participants are monitored for safety and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IPG1094
What this could lead to
If successful, this study will provide key data on how IPG1094 behaves in the body, supporting future trials for potential therapeutic uses.
What could go wrong
This is an early phase 1 trial in only 24 healthy volunteers, so results may not predict effects in patients. The drug may cause side effects or fail in later studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Xuhui Central Hospital
Shanghai, Xuhui, 200031, China
Contact Phone: •••-•••-•••• Email: •••••@•••••